Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Connected Prehabilitation Program During Neo Adjuvant Chemotherapy (TRAINING)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04451369
Recruitment Status : Not yet recruiting
First Posted : June 30, 2020
Last Update Posted : June 30, 2020
Sponsor:
Information provided by (Responsible Party):
Institut Paoli-Calmettes

Brief Summary:

NACT is a heavy oncologic treatment, which can impair functional capacity, nutritional and emotional status. These three impairments are often ignored and not taken into account in the pre-therapeutic evaluations but are correlated with postoperative morbidity and mortality after major surgery.

Recently, a prehabilitation before surgery, including physical, nutritional and psycho-social support, has been defined. From a literature review, the maximum oxygen uptake (VO2 max) seems to constitute a strong evaluation factor reflecting physical fitness, easily measured with a cardiopulmonary exercise test (CPET) at maximal effort.

Several studies have shown beneficial effects of trimodal prehabilitation programs on postoperative functional capacity, return to daily activities and pain relief.

Home-based program and connected devices may improve the feasibility and the compliance to this program.

The hypothesis of this study is that performing a connected supervised home-based and patient-tailored multimodal prehabilitation program from diagnosis to surgery (with or without ERAS program) during NACRT, for patients managed for ovarian cancer, will limit physical fitness alteration and will positively affect postoperative outcomes.

Our study consists in an early and multidimensional (combining nutritional, physical, emotional and medical support) prehabilitation program during NACT for patients with ovarian cancer, in order to limit physical alteration before surgical treatment, and therefore improve postoperative outcomes. It will include a home-based prehabilitation program, in order to allow care access to all eligible patients.


Condition or disease Intervention/treatment Phase
Ovarian Cancer Other: Prehabilitation program Not Applicable

Detailed Description:

The main objective will be to determine if a prehabilitation program during NACT, for patients treated for an advanced ovarian cancer will limit physical alteration before major abdomino-pelvic surgery, compared to a control group without prehabilitation program. The primary endpoint will be the comparison of the variation of VO2 max, between baseline and surgery, in the prehabilitation group vs control group: VO2 max will be measured with a cardiopulmonary exercise test (CPET) at maximal effort.

This prospective, multicentric randomized control trial will be conducted in 7 French comprehensive cancer Centers or University Hospital, in compliance with inclusion criteria. After an initial evaluation, patients will be randomized in two groups: Prehabilitation group (P group) and a Control group (C group).

For the P group, after baseline evaluation, we will be offering from diagnosis to surgery, during the NACT:

  • A standardized, patient-tailored preoperative physical activity training program will be performed at home, from diagnosis to surgery. Supervision will be done with connected device (connected watches) and activity will be adapted,
  • A nutritional care established in respect of the SFNEP-SFNCM guidelines. Nutritional support will be adapted by a dietician according to information transmitted daily (connected body fat weight scale),
  • A psychological support with coping strategies.

For the C group: Patients with ovarian cancer will undergo NACT after baseline evaluation without prehabilitation program.

After NACT, for both groups, major abdomino-pelvic surgery will be done with or without ERAS pathway, according to the practice in each center.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 136 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Multicenter Randomized Study Comparing Neo Adjuvant Chemotherapy for Patients Managed for Ovarian Cancer With or Without a Connected Prehabilitation Program
Estimated Study Start Date : October 2020
Estimated Primary Completion Date : September 2022
Estimated Study Completion Date : September 2027

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ovarian Cancer

Arm Intervention/treatment
No Intervention: Control group
Group without prehabilitation program before surgery
Experimental: Prehabilitation group
Group will follows a prehabilitation program before surgery
Other: Prehabilitation program
physical, nutritional and psycho-social supports before surgery




Primary Outcome Measures :
  1. To determine if a prehabilitation program during NACT, for patient managed with advanced ovarian cancer (AOC) will limit physical alteration before surgery, compared to a control group without prehabilitation program (change between 3 timepoints). [ Time Frame: baseline, 15 days before surgery and 3 moths before surgery ]
    CHANGE of VO2 max between baseline (inclusion) and surgery (preoperative), in the prehabilitation group vs control group. VO2 max will be measured during a cardiopulmonary exercise test (CPET).


Secondary Outcome Measures :
  1. to compare physical outcomes between both groups [ Time Frame: baseline, before surgery, and 3 months after surgery ]
    o International Physical Activity Questionnaire (IPAQ) , administered at inclusion and at the time of surgery and after surgery

  2. to compare physical outcomes between both groups [ Time Frame: baseline, before surgery, and 3 months after surgery ]
    Muscular strength evaluated with dynamometer (brachial biceps)

  3. to compare Quality of Life, emotional outcomes between both groups [ Time Frame: baseline, before surgery, and 3 months after surgery ]
    Psychological status evaluated by the Hospital Anxiety and Depression Scale (HADS) (Annex 2)

  4. to compare Quality of Life, emotional outcomes between both groups [ Time Frame: baseline, before surgery, and 3 months after surgery ]
    Cancer related quality of life (QoL) evaluated by using the self-reported European Organization for Research and Treatment of Cancer (EORTC) core questionnaire (QLQ-C30) (Annex 3)

  5. to compare Quality of Life, emotional outcomes between both groups [ Time Frame: baseline, before surgery, and 3 months after surgery ]
    Motivation evaluated by a free interview and a coping strategy.

  6. to compare nutritional outcomes between both groups [ Time Frame: baseline, before surgery, and 3 months after surgery ]
    Change Body Mass Index (BMI)

  7. to compare nutritional outcomes between both groups [ Time Frame: baseline, before surgery, and 3 months after surgery ]
    Muscle mass evaluated with the Computed tomography-derived

  8. to compare nutritional outcomes between both groups [ Time Frame: baseline, before surgery, and 3 months after surgery ]
    skeletal muscle index measured by skeletal muscle mass cross-sectional area at L3/height2

  9. to compare nutritional outcomes between both groups [ Time Frame: baseline, before surgery, and 3 months after surgery ]
    Weight in kg

  10. to compare Surgical Morbidity rate between both groups [ Time Frame: at day 30 and day 90 (3 months) after surgery ]
    Clavien-Dindo classification

  11. to compare Surgical Morbidity rate between both groups [ Time Frame: at day 30 and day 90 (3 months) after surgery ]
    NCI-CTCAE v 5.0 classification



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Ovarian cancer.
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient must have signed the written consent,
  2. Age ≥ 18 years,
  3. Patient with advanced ovarian cancer (AOC), FIGO Stage III - IV, undergoing surgery,
  4. Patient with neo adjuvant chemotherapy (min 3 cycles, max 6 cycles),
  5. Capability to perform a cardiopulmonary exercise test (CPET)
  6. Patient affiliated to the national "Social Security" regimen or beneficiary of this regimen.

Exclusion Criteria:

  1. Patient with cognitive impairment,
  2. Pregnancy,
  3. Neoadjuvant treatment contraindications,
  4. Physical adapted activity program contraindication,
  5. No possibility to have access to connected devices or do not have a smartphone or a computer
  6. Patient deprived of liberty or placed under the authority of a tutor,
  7. Patient considered socially or psychologically unable to comply with the procedure and the required medical follow-up.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04451369


Contacts
Layout table for location contacts
Contact: Dominique GENRE, Dr +33 4 91 22 37 78 drci.up@ipc.unicancer.fr

Sponsors and Collaborators
Institut Paoli-Calmettes
Layout table for additonal information
Responsible Party: Institut Paoli-Calmettes
ClinicalTrials.gov Identifier: NCT04451369    
Other Study ID Numbers: TRAINING-01-IPC 2018-039
First Posted: June 30, 2020    Key Record Dates
Last Update Posted: June 30, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type